# Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

> **NCT04599556** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 81 (estimated)

## Conditions studied

- CD7+ Acute Leukemia
- CD7+ Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD7 CAR-T

## Key facts

- **NCT ID:** NCT04599556
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2023-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599556, "Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04599556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*